The Health Impact of Using Anti-PD-1 Agents to Treat Early-Stage Cancer in Belgium
The investment in and use of innovative anti-PD-1 agents for the treatment of early-stage cancers would have a positive health impact for Belgium and align with the high standards in cancer care called for in Europe's Beating Cancer Plan.
Authors
- Saar Vandekeere
- Demet Sönmez
- Tyler Mantaian
- Olivier Ethgen
- Raquel Aguiar‐Ibáñez (ORCID: https://orcid.org/0000-0002-3839-6966)
- André Bento‐Abreu (ORCID: https://orcid.org/0000-0002-4715-3990)
- Carolina Lara Neves (ORCID: https://orcid.org/0000-0003-0734-663X)
Institutions
- University of Liège (BE)
- Utrecht University (NL)
- Merck Canada Inc. (Canada) (CA)
- MSD (Sweden) (SE)
- MSD (Belgium) (BE)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1007/s40487-025-00357-z
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Merck